Showing results (341-350 of 651) with videos related to
Sort By:
Pageof 66
Diabetes, Obesity & Metabolism|September 28, 2021
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trialPeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 2, 2024
Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6Ellen M Apperloo, David Z I Cherney, Anja Birk Kuhlman, et al.Scientific Reports|September 9, 2024
Transcutaneous vagus nerve stimulation has no anti-inflammatory effect in diabetesTina Okdahl, Huda Kufaishi, Ditte Kornum, et al.European Heart Journal. Cardiovascular Pharmacotherapy|October 9, 2024
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysisBertram Pitt, Rajiv Agarwal, Stefan D Anker, et al.Kidney International|April 23, 2025
Analysis of the prespecified FIDELITY pooled patient dataset examined the efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rateSankar D Navaneethan, Stefan D Anker, Gerasimos Filippatos, et al.BMJ Open Diabetes Research & Care|September 14, 2021
Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trialEmilie H Zobel, Asger Wretlind, Rasmus S Ripa, et al.Cardiovascular Diabetology|November 26, 2022
The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitusCarlos Puig-Jové, Josep Julve, Esmeralda Castelblanco, et al.Diabetes Care|January 13, 2017
Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 DiabetesGert Mayer, Hiddo J L Heerspink, Constantin Aschauer, et al.Clinical Journal of the American Society of Nephrology : CJASN|January 14, 2026
Finerenone in People with Chronic Kidney Disease, Type 2 Diabetes, and History of NephrectomyJair Munoz Mendoza, Matthew R Weir, Stefan D Anker, et al.Kidney International Reports|February 12, 2024
Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney DiseaseTarunveer S Ahluwalia, Teemu K E Rönkkö, Mie K Eickhoff, et al.Pageof 66